The Technical Analyst
Dynegy Inc. [DYN]
Exchange: NYSE Sector: Healthcare Industry: Biotechnology
Dynegy Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
0.89% $23.86
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 935.19 mill |
| EPS: | -3.95 |
| P/E: | -6.04 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 81.11 mill |
| Avg Daily Volume: | 1.414 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -6.04 | sector: PE 15.43 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.15x |
| Company: PE -6.04 | industry: PE 40.47 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$1.579 (-93.38%) $-22.28 |
| Date: 2024-04-20 |
| Expected Trading Range (DAY) |
|---|
|
$ 21.87 - 25.85 ( +/- 8.33%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-25 | Cox John | Sell | 0 | Common Stock |
| 2023-07-11 | Mcneill Jonathan | Buy | 35 000 | Stock option (right to buy) |
| 2024-03-25 | Cox John | Buy | 679 853 | Stock Option (Right to Buy) |
| 2024-03-25 | Cox John | Sell | 0 | Common Stock |
| 2024-03-08 | High Susanna Gatti | Sell | 26 908 | Common Stock |
| INSIDER POWER |
|---|
| -35.84 |
| Last 100 transactions |
| Buy: 1 463 541 | Sell: 3 129 182 |
Forecast:
16:00 - $23.89
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $23.89
Forecast 2: 16:00 - $23.89
Forecast 3: 16:00 - $23.89
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $23.86 (0.89% ) |
| Volume | 0.929 mill |
| Avg. Vol. | 1.414 mill |
| % of Avg. Vol | 65.72 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For DYN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $22.58 | N/A | Active |
|---|
DYN
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Latest Press Releases
2024-03-27 16:05:00 - Press Release
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) To Newly Appointed President And Chief Executive Officer
Waltham, mass., march 27, 2024 (globe newswire) -- dyne therapeutics, inc. (nasdaq: dyn), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that it has granted an inducement equity award to its newly appointed president and chief executive officer, john g. cox. the award was approved by the compensation committee of dyne and was made as an inducement material to mr. cox's acceptance of employment with dyne under dyne's 2024 inducement stock incentive plan in accordance with nasdaq listing rule 5635(c)(4).
2024-03-27 08:30:00 - Press Release
Dyne Therapeutics To Present At The Cantor Virtual Muscular Dystrophy Symposium
Waltham, mass., march 27, 2024 (globe newswire) -- dyne therapeutics, inc . (nasdaq: dyn), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that wildon farwell, m.d., mph, chief medical officer, and oxana beskrovnaya, ph.d., chief scientific officer, are scheduled to participate in a fireside chat during the cantor virtual muscular dystrophy symposium on tuesday, april 2, 2024 at 9:50 a.m. et.
2024-03-25 07:30:00 - Press Release
Dyne Therapeutics Announces Ceo Transition
- john cox, industry leader with global experience in rare disease commercialization, joins dyne as president and ceo -
2024-03-13 07:30:00 - Press Release
Dyne Therapeutics To Present At Stifel 2024 Virtual Cns Days
Waltham, mass., march 13, 2024 (globe newswire) -- dyne therapeutics, inc. (nasdaq: dyn), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the stifel 2024 virtual cns days on wednesday, march 20, 2024 at 8:30 a.m. et.
2024-03-05 07:30:00 - Press Release
Dyne Therapeutics Reports Fourth Quarter And Full Year 2023 Financial Results And Recent Business Highlights
- positive initial clinical data from achieve trial in dm1 patients and deliver trial in dmd patients demonstrated proof-of-concept, validating the promise of the force™ platform and targeted delivery to muscle -
Latest News
2024-03-13 07:30:00 - GlobeNewsWire
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
WALTHAM, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Stifel 2024 Virtual CNS Days on Wednesday, March 20, 2024 at 8:30 a.m. ET.
2024-03-05 14:48:29 - Seeking Alpha
Dyne: H2 2024 Muscle Disease Data Could Boost Value
2024-02-01 07:30:00 - GlobeNewsWire
Dyne Therapeutics to Present at February Investor Conferences
WALTHAM, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present at the following investor conferences in February:
2024-01-22 22:14:30 - InvestorPlace
7 Speculative Stocks to Double Your Money THIS Year
While investors should probably direct the majority of their market-earmarked funds toward slow-and-steady ideas – à la Warren Buffett – sometimes, we end up with gambling money. And in that case, speculative stocks to double your money might make sense.
2024-01-05 07:30:00 - GlobeNewsWire
Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Joshua Brumm, president and chief executive officer, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2024 at 2:15 p.m. PT (5:15 p.m. ET).
2024-01-04 12:54:48 - Proactive Investors
Dyne Therapeutics surpasses $1B valuation in strong start to 2024
Dyne Therapeutics is off to a strong start in 2024 with positive trial data from its Duchenne muscular dystrophy (DMD) program. The company released positive initial proof-of-concept data for its two lead programs, targeting muscle diseases DM1 and DMD.
2024-01-03 08:19:59 - InvestorPlace
Why Is Dyne Therapeutics (DYN) Stock Up 39% Today?
Dyne Therapeutics (NASDAQ: DYN ) stock is taking off on Wednesday after the muscle disease company announced positive clinical trial data. According to a press release from Dyne Therapeutics, its ACHIEVE trial and DELIVER trial have both turned in positive results.
2024-01-03 08:19:00 - Market Watch
Dyne Therapeutics stock gains, Sarepta falls after muscular dystrophy trial results
Dyne Therapeutics Inc. shares DYN, -1.80% jumped 40% premarket on Wednesday after the company released new data from trials of two investigational treatments for genetic muscle disorders. The experimental treatment DYNE-101 showed early dose-dependent results in patients with myotonic dystrophy type 1, Dyne said in a release.
2024-01-02 16:05:00 - GlobeNewsWire
Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER Trials
WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it plans to report initial clinical data from its Phase 1/2 ACHIEVE and DELIVER trials on January 3, 2024, and to host a virtual event at 8:00 a.m. ET. The company intends to issue a press release prior to the start of the event.
2023-11-13 18:59:01 - InvestorPlace
3 of the Best Cheap Stocks Under $20 to Buy Now: November Edition
After dropping to 52-week lows, the markets have been rallying lately. That has traders and investors scrambling for cheap stocks under $20 to buy.